You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
信達生物(1801.HK)與葆元醫藥就Taletrectinib達成獨家許可協議
阿思達克 06-01 08:58
信達生物(1801.HK)公布,公司與葆元醫藥簽訂獨家許可協議,以推進葆元醫藥的主要候選藥物taletrectinib,一款下一代有效靶向ROS1和NTRK的酪氨酸激(酉每)抑制劑(TKI),在大中華區(包括內地、香港、澳門及台灣)的開發及商業化。

據協議條款,公司將獲得taletrectinib在大中華區的獨家共同開發和商業化權利。葆元醫藥將繼續負責內地的taletrectinib的臨床開發和註冊報批,和大中華地區的臨床生產和商業化生產。公司有權在香港、澳門和台灣地區共同開發taletrectinib和負責註冊報批。

根據協議,葆元醫藥將獲得總額可達1.89億美元的先期付款及開發費用資助和潛在里程碑付款,以及基於taletrectinib在大中華區年度淨銷售額的特許權使用費。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account